CL2013003358A1 - Uso de un fumarato para preparar un medicamento útil para tratar esclerosis múltiple. - Google Patents

Uso de un fumarato para preparar un medicamento útil para tratar esclerosis múltiple.

Info

Publication number
CL2013003358A1
CL2013003358A1 CL2013003358A CL2013003358A CL2013003358A1 CL 2013003358 A1 CL2013003358 A1 CL 2013003358A1 CL 2013003358 A CL2013003358 A CL 2013003358A CL 2013003358 A CL2013003358 A CL 2013003358A CL 2013003358 A1 CL2013003358 A1 CL 2013003358A1
Authority
CL
Chile
Prior art keywords
fumarate
prepare
multiple sclerosis
treat multiple
useful medication
Prior art date
Application number
CL2013003358A
Other languages
English (en)
Spanish (es)
Inventor
Katherine Dawson
Gilmore ONEILL
Alfred Sandrock
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47217796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013003358(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of CL2013003358A1 publication Critical patent/CL2013003358A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CL2013003358A 2011-05-26 2013-11-22 Uso de un fumarato para preparar un medicamento útil para tratar esclerosis múltiple. CL2013003358A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161490572P 2011-05-26 2011-05-26
US201261625624P 2012-04-17 2012-04-17

Publications (1)

Publication Number Publication Date
CL2013003358A1 true CL2013003358A1 (es) 2014-08-01

Family

ID=47217796

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013003358A CL2013003358A1 (es) 2011-05-26 2013-11-22 Uso de un fumarato para preparar un medicamento útil para tratar esclerosis múltiple.

Country Status (19)

Country Link
US (1) US20140163100A1 (enExample)
EP (1) EP2713724A4 (enExample)
JP (1) JP2014515373A (enExample)
KR (1) KR20140036257A (enExample)
CN (1) CN103732062A (enExample)
AU (1) AU2012258558A1 (enExample)
BR (1) BR112013030169A2 (enExample)
CA (1) CA2836480A1 (enExample)
CL (1) CL2013003358A1 (enExample)
CO (1) CO6811862A2 (enExample)
EA (1) EA201391578A1 (enExample)
EC (1) ECSP13013117A (enExample)
IL (1) IL229448A0 (enExample)
MX (1) MX2013013781A (enExample)
PE (1) PE20141316A1 (enExample)
PH (1) PH12013502443A1 (enExample)
SG (1) SG195049A1 (enExample)
WO (1) WO2012162669A1 (enExample)
ZA (1) ZA201308681B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004010531T2 (de) 2003-09-09 2008-07-03 Fumapharm Ag Verwendung von fumarsäure-derivaten zur behandlung von herzinsuffizienz und asthma
EP3470064A1 (en) 2004-10-08 2019-04-17 Fwp Ip Aps Controlled release pharmaceutical compositions comprising a fumaric acid ester
NZ608196A (en) 2008-08-19 2014-09-26 Xenoport Inc Prodrugs of methyl, hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
MX355421B (es) 2011-06-08 2018-04-18 Biogen Ma Inc Proceso para preparar fumarato de dimetilo cristalino y de alta pureza.
EP2887934A1 (en) 2012-08-22 2015-07-01 XenoPort, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US20140348915A9 (en) 2012-08-22 2014-11-27 Xenoport, Inc. Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof
US20140057918A1 (en) * 2012-08-22 2014-02-27 Xenoport, Inc. Methods of Use for Monomethyl Fumarate and Prodrugs Thereof
EP3566701A1 (en) 2012-12-21 2019-11-13 Biogen MA Inc. Deuterium substituted fumarate derivatives
ES2955137T3 (es) 2013-03-14 2023-11-28 Alkermes Pharma Ireland Ltd Profármacos de fumaratos y su uso en el tratamiento de diversas enfermedades
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
US9416096B2 (en) 2013-09-06 2016-08-16 Xenoport, Inc. Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use
CN103724198A (zh) * 2013-11-28 2014-04-16 镇江圣安医药有限公司 富马酸二甲酯的新型衍生物及其应用
CA2940845C (en) 2014-02-24 2019-09-24 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9326965B2 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
AU2014414316B2 (en) * 2014-10-27 2020-04-09 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
MA40985A (fr) * 2014-11-17 2017-09-26 Biogen Ma Inc Méthodes de traitement de la sclérose en plaques
MA41139A (fr) * 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
KR102590068B1 (ko) 2014-12-11 2023-10-16 액테리온 파마슈티칼 리미티드 선택적 s1p1 수용체 효능제에 대한 투약 섭생
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19721099C2 (de) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
CN101056624A (zh) * 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
EP1951206A1 (en) * 2005-10-07 2008-08-06 Aditech Pharma AB Controlled release pharmaceutical compositions comprising a fumaric acid ester
PT2653873T (pt) * 2007-02-08 2022-07-26 Biogen Ma Inc Composições e utilizações para o tratamento de esclerose múltipla
LT2139467T (lt) * 2007-02-08 2016-10-10 Biogen Ma Inc. Neuroapsauga, sergant demielinizuojančia liga
NZ608196A (en) * 2008-08-19 2014-09-26 Xenoport Inc Prodrugs of methyl, hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
CN102427727A (zh) * 2009-04-29 2012-04-25 比奥根艾迪克Ma公司 神经变性和神经炎症的治疗

Also Published As

Publication number Publication date
PE20141316A1 (es) 2014-10-01
US20140163100A1 (en) 2014-06-12
MX2013013781A (es) 2014-01-08
AU2012258558A1 (en) 2013-05-02
BR112013030169A2 (pt) 2016-08-09
KR20140036257A (ko) 2014-03-25
WO2012162669A1 (en) 2012-11-29
SG195049A1 (en) 2013-12-30
EP2713724A1 (en) 2014-04-09
EA201391578A1 (ru) 2014-05-30
EP2713724A4 (en) 2015-03-11
IL229448A0 (en) 2014-01-30
CO6811862A2 (es) 2013-12-16
JP2014515373A (ja) 2014-06-30
CA2836480A1 (en) 2012-11-29
CN103732062A (zh) 2014-04-16
ZA201308681B (en) 2017-11-29
ECSP13013117A (es) 2014-06-30
PH12013502443A1 (en) 2019-03-22

Similar Documents

Publication Publication Date Title
CL2013003358A1 (es) Uso de un fumarato para preparar un medicamento útil para tratar esclerosis múltiple.
EP2667915A4 (en) INJEKTOR
DK2813573T1 (da) ADAM6 mus
EP2699293A4 (en) SELF-INJECTOR APPARATUS
BR112013020613A2 (pt) autoinjetor
CO6801647A2 (es) Formulación para anticuerpo anti-α4β7
CO6801648A2 (es) Formulación para anticuerpo anti-α4β7
DK3542843T3 (da) Engangsinjektionspen til flere anvendelser
BR112013033444A2 (pt) formulações para terapia de ferida
SI3091029T1 (sl) Pripravki protiteles proti IL13
EP2773641A4 (en) BIARYLETHERSULFONAMIDES AND THEIR USE AS MEDICAMENTS
SI3513793T1 (sl) Heterociklilamini kot zaviralci PI3K
DK2709667T3 (da) Bio-orthogonal lægemiddelaktivering
BR112013022161A2 (pt) dispositivo para injeção
BR112014001450A2 (pt) dispositivos intravaginais para distribuição de droga
LT2701773T (lt) Injekcinio švirkšto dozės kreiptuvai
BR112014013843A2 (pt) uso de dispositivos para o tratamento de doenças neurológicas
BR112014002830A2 (pt) fotossensibilizador para uso terapêutico
PT2758373T (pt) Processos para a preparação de brometo de n-etil-2-metilpiridínio e brometo de n-etil-metilpiridínio
CO6940380A2 (es) Espray para heridas
BR112013024413A2 (pt) compostos e métodos para a preparação de diarilpropanos
CL2013002581A1 (es) Compuestos derivados de indol-y -bencimidazol carboxamidas; pprocedimiento para prepararlos; uso de dichos còmpuestos para producir plaguicidas; y compuestos intermediarios.
BR112013032534A2 (pt) interface gráfica para usuário
IL229081A0 (en) Isoxazolines as therapeutic agents
PT2739266T (pt) Soluções anti-inflamatórias estáveis para injecção